Adimab Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 135

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Adimab General Information

Description

Developer of yeast-based human antibody discovery and engineering technologies designed to develop therapeutic antibodies. The company specializes in antibody discovery, affinity maturation, and production using yeast-based platforms, enabling biopharmaceutical companies to develop therapeutic candidates for cancer, autoimmune disorders, and infectious diseases.

Contact Information

Website
www.adimab.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7 Lucent Drive
  • Lebanon, NH 03766
  • United States
+1 (603)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 7 Lucent Drive
  • Lebanon, NH 03766
  • United States
+1 (603)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adimab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Apr-2026 Completed Generating Revenue
8. Later Stage VC 29-Dec-2020 Completed Generating Revenue
7. Later Stage VC 01-Feb-2015 Completed Generating Revenue
6. Later Stage VC (Series F) 16-Apr-2012 Completed Generating Revenue
5. Later Stage VC (Series E) 29-Nov-2010 Completed Generating Revenue
4. Later Stage VC (Series D) 01-Oct-2009 Completed Generating Revenue
3. Later Stage VC (Series C) 20-Nov-2008 Completed Startup
2. Early Stage VC (Series B) 25-Mar-2008 $3.18M $9.5M Completed Startup
1. Early Stage VC (Series A) 20-Jul-2007 $6.32M $6.32M Completed Startup
To view Adimab’s complete valuation and funding history, request access »

Adimab Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B
Series A2 1,574,133 $0.001000 $3.76 $3.76 1x $3.76 22.67%
Series A1 300,000 $0.001000 $1.33 $1.33 1x $1.33 4.32%
To view Adimab’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Adimab Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of yeast-based human antibody discovery and engineering technologies designed to develop therapeutic antibodie
Drug Discovery
Lebanon, NH
135 As of 2026

Geneva, Switzerland
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adimab Competitors (73)

One of Adimab’s 73 competitors is Light Chain Bioscience, a Formerly PE-Backed company based in Geneva, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
Dren Bio Venture Capital-Backed San Carlos, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
XBiotech Corporation Austin, TX
You’re viewing 5 of 73 competitors. Get the full list »

Adimab Patents

Adimab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260132207-A1 Activin type 2 receptor binding proteins and uses thereof Pending 31-Jul-2025
WO-2026226938-A1 Anti-gdf-15 antibodies and uses thereof Pending 24-Apr-2025
WO-2026006458-A1 Anti-cd3 antibodies and compositions and methods related thereto Pending 25-Jun-2024
WO-2026006458-A9 Anti-cd3 antibodies and compositions and methods related thereto Pending 25-Jun-2024
WO-2025184137-A1 Influenza antibodies and methods of use thereof Pending 27-Feb-2024 C07K16/108
To view Adimab’s complete patent history, request access »

Adimab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adimab Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apricot Capital (Shanghai) Venture Capital Minority
Angel (individual) Minority
Lux Capital Venture Capital Minority
Premji Invest (US) Growth/Expansion Minority
Saints Capital Secondary Buyer Minority
You’re viewing 5 of 7 investors. Get the full list »

Adimab Investments & Acquisitions (3)

Adimab’s most recent deal was a Later Stage VC with Invivyd for . The deal was made on 19-Apr-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Invivyd 19-Apr-2021 Later Stage VC Drug Discovery
Invivyd 10-Nov-2020 Early Stage VC Drug Discovery
GenetaStix 26-Jul-2007 Merger/Acquisition Biotechnology
To view Adimab’s complete investments and acquisitions history, request access »

Adimab FAQs

  • When was Adimab founded?

    Adimab was founded in 2007.

  • Where is Adimab headquartered?

    Adimab is headquartered in Lebanon, NH.

  • What is the size of Adimab?

    Adimab has 135 total employees.

  • What industry is Adimab in?

    Adimab’s primary industry is Drug Discovery.

  • Is Adimab a private or public company?

    Adimab is a Private company.

  • What is Adimab’s current revenue?

    The current revenue for Adimab is .

  • How much funding has Adimab raised over time?

    Adimab has raised $143M.

  • Who are Adimab’s investors?

    Apricot Capital (Shanghai), , Lux Capital, Premji Invest (US), and Saints Capital are 5 of 7 investors who have invested in Adimab.

  • Who are Adimab’s competitors?

    Light Chain Bioscience, Dren Bio, CytomX Therapeutics, Sarepta Therapeutics, and XBiotech are some of the 73 competitors of Adimab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process